Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11905372 | 0.82 | ESR1 (0.35) | ESR1ESR2MAPTPDE4B | |
| SCHEMBL8520332 | 0.77 | ESR1 (0.35) | ESR1ESR2 | |
| SCHEMBL3949561 | 0.76 | DUT (0.31) | — | |
| SCHEMBL48955 | 0.75 | ESR1 (0.41) | ESR1ESR2MAPT | |
| SCHEMBL1699112 | 0.72 | MAPK1 (0.31) | — | |
| SCHEMBL121414 | 0.72 | ESR1 (0.42) | ESR1ESR2MAPT | |
| SCHEMBL18125 | 0.69 | ESR1 (0.39) | ESR1ESR2MAPT | |
| SCHEMBL211428 | 0.69 | ESR1 (0.39) | ESR1ESR2MAPT | |
| SCHEMBL536490 | 0.69 | ESR1 (0.39) | ESR1ESR2MAPT | |
| SCHEMBL11488036 | 0.69 | ESR1 (0.39) | ESR1ESR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567354-B2 | Amino acid-modified silane compounds and making method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20120209020-A1 | AMINO ACID-MODIFIED SILANE COMPOUNDS AND MAKING METHOD | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| US-6482827-B1 | Matrix metalloproteinase inhibitors | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-11-19 | — | — | US | disclosed |
| EP-0925289-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 1999-06-30 | — | — | EP | disclosed |
| EP-0920414-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 1999-06-09 | — | — | EP | disclosed |
| WO-1999002510-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-01-21 | — | — | WO | disclosed |
| WO-1997049674-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120209020-A1 | AMINO ACID-MODIFIED SILANE COMPOUNDS AND MAKING METHOD | BCAT2, BCAT1, ASNS | ESR1 2872/4885ESR2 2972/4885MAPT 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.